HC Wainwright maintains Buy on Agios Pharmaceuticals
HC Wainwright & Co. analyst Emily Bodnar maintained a Buy rating on Agios Pharmaceuticals and lowered the price target to $52 from $54.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Emily Bodnar has maintained a Buy rating for Agios Pharmaceuticals while adjusting the valuation outlook. The firm lowered the price target to $52, down from the previous $54 target.
Rating and Price Target Details
The revision follows a review of the company's position. The table below details the updated rating and price targets provided by the analyst.
| Metric | Value |
|---|---|
| Rating | Buy |
| New Price Target | $52 |
| Previous Price Target | $54 |
The adjusted price target reflects the firm's current analysis of the stock's potential.
What specific factors led to the $2 reduction in the price target despite the Buy rating?
How might this valuation adjustment influence investor sentiment towards Agios Pharmaceuticals in the short term?
What upcoming clinical or regulatory milestones could drive further revisions to the price target?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
